Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Bohdan Kadlec"'
Publikováno v:
The Scientific World Journal, Vol 2014 (2014)
Patients with lung cancer experience elevated risk of venous thromboembolism. Cancer patients with thrombosis have a shorter life expectancy and the occurrence of VTE worsens the quality of life and may delay, interrupt, or completely halt the cancer
Externí odkaz:
https://doaj.org/article/27899485892c420c81a34ae7b9857135
Autor:
Bohdan Kadlec
Publikováno v:
Onkologie. 14:135-138
Alectinib - Alecenza® je vysoce selektivni inhibitor tyrosinkinazy ALK, který ve studiich prokazal ucinnost vůci mutovaným formam ALK, vcetně mutaci rezistentnich ke crizotinibu. Jeho výhodou je, že prostupuje přes hematoencefalickou barieru
Autor:
Ondřej Málek, Karel Hejduk, Ivana Peterová-Čierná, Bohdan Kadlec, Martina Vasakova, Jana Skřičková, Tomáš Nebeský
Publikováno v:
Klinicka onkologie. 34
Decisions about the treatment of a patient with lung cancer depend on the clinical stage of the disease, morphological diagnosis, examination of predictive markers and overall clinical condition; the wishes of a well-informed patient must also be tak
Autor:
Lenka Jakubíková, Jana Skřičková, Jana Špeldová, Marcela Tomíšková, Ondřej Venclíček, Bohdan Kadlec, Blanka Robešová, Zdeněk Merta
Publikováno v:
Onkologie. 12:175-181
Při lecebne rozvaze po stanoveni diagnozy je v soucasnosti snahou vybrat pro nemocneho s nemalobuněcným karcinomem (NSCLC) lek, u ktereho je prokazano, že je ucinný u nadoru, který nese urcite morfologicke a/nebo molekularně geneticke znaky. N
Publikováno v:
Vnitrni lekarstvi. 63(11)
Non-small cell lung cancer (NSCLC) represents 80 % of diseases considering all patients with lung cancer. NSCLC comprises all histological types except for the small cell cancer. The treatment is chosen based on a clinical stage, morphological diagno
Publikováno v:
D26. PNEUMOCYSTIS PNEUMONIA: UPDATES TO DETECTION, DEFENSES AND LUNG DAMAGE.
As shown in the paper, Pneumocystis jirovecii (formerly carinii)can be associated with pneumonia even in patients who are HIV-negative and do not have malignancies.
Autor:
Jana Kaplanová, Irena Vašutová, Ivo Hanke, Pavel Turčáni, Jana Skrickova, Theodor Horváth, Jindrich Vomela, Adam Svobodník, Lenka Babičková, Marcela Tomíšková, Bohdan Kadlec
Publikováno v:
Journal of Thoracic Oncology. 2(8)
Results of seven years of surgical treatment of non-small cell lung cancer are presented in this paper. As neoadjuvant treatment was also performed in this group of patients, its influence on the overall outcome could be evaluated.
Autor:
Jana Skřičková, Jiří Bartoš, Vítězslav Kolek, Ivona Grygárková, Bohdan Kadlec, J. Chalupa, P. Reiterer, Ondřej Venclíček, Helena Čoupková, T. Janásková
Publikováno v:
Lung Cancer. 77:S37-S38
The purpose of this trial was to evaluate the activity and feasibility of CBDCA together with full oral vinorelbin (NVBO) in 1st line treatment NSCLC patients. This is a prospective nerandomizovanou study of 259 patients.This is a prospective nerando
Autor:
K. Chroust, Bohdan Kadlec, Marcela Tomíšková, L. Kren, Z. Pavlovsky, I. Vasutova, Jana Skrickova, Y. Stankova, Lenka Babičková
Publikováno v:
Lung Cancer. 64:S30-S31
A variety of parameters acknowledged to be markers of proliferation activity of non-small cell lung cancer were followed up and discussed in this paper.
Autor:
Dimka Sixtová, Petr Zatloukal, Rostislav Vyzula, Leona Koubková, Milada Zemanova, Helena Čoupková, Karel Hejduk, Jana Skrickova, František Salajka, Vitezslav Kolek, Stanislav Špelda, Jaromír Roubec, Miloš Pešek, Bortlicek Zbynek, Bohdan Kadlec
Publikováno v:
ResearcherID
e18062 Background: Erlotinib is approved for NSCLC treatment in Czech Rep since 2005. This analysis was performed to analyze the profile of pts treated with erlotinib longer than 6 months. Methods: This retrospective analysis evaluates data from Czec